Neuroendocrine tumors rise in incidence, often found incidentally, prompting multidisciplinary diagnosis, somatostatin receptor PET imaging, and evolving radioligand therapy options.
Simron Singh, MD, Odette Cancer Centre
Advertisement
Articles by Simron Singh, MD, Odette Cancer Centre
NET cases rise steadily as survival boosts prevalence; experts argue it’s no longer rare, driving urgent demand for more resources and treatments.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5